495 related articles for article (PubMed ID: 28092469)
1. Investigational drugs in recent clinical trials for treatment-resistant depression.
Garay RP; Zarate CA; Charpeaud T; Citrome L; Correll CU; Hameg A; Llorca PM
Expert Rev Neurother; 2017 Jun; 17(6):593-609. PubMed ID: 28092469
[TBL] [Abstract][Full Text] [Related]
2. Esketamine for treatment resistant depression.
Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
[No Abstract] [Full Text] [Related]
3. An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine.
De Berardis D; Tomasetti C; Pompili M; Serafini G; Vellante F; Fornaro M; Valchera A; Perna G; Volpe U; Martinotti G; Fraticelli S; Di Giannantonio M; Kim YK; Orsolini L
Curr Top Med Chem; 2020; 20(7):554-584. PubMed ID: 32003691
[TBL] [Abstract][Full Text] [Related]
4. Investigational drugs for treating agitation in persons with dementia.
Garay RP; Citrome L; Grossberg GT; Cavero I; Llorca PM
Expert Opin Investig Drugs; 2016 Aug; 25(8):973-83. PubMed ID: 27232589
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
Kryst J; Kawalec P; Pilc A
Expert Opin Pharmacother; 2020 Jan; 21(1):9-20. PubMed ID: 31663783
[No Abstract] [Full Text] [Related]
6. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
7. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
8. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
[TBL] [Abstract][Full Text] [Related]
9. Esketamine: A Novel Option for Treatment-Resistant Depression.
Bozymski KM; Crouse EL; Titus-Lay EN; Ott CA; Nofziger JL; Kirkwood CK
Ann Pharmacother; 2020 Jun; 54(6):567-576. PubMed ID: 31795735
[No Abstract] [Full Text] [Related]
10. Esketamine and rapastinel, but not imipramine, have antidepressant-like effect in a treatment-resistant animal model of depression.
Pereira VS; Joca SRL; Harvey BH; Elfving B; Wegener G
Acta Neuropsychiatr; 2019 Oct; 31(5):258-265. PubMed ID: 31230597
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
Doherty T; Wajs E; Melkote R; Miller J; Singh JB; Weber MA
CNS Drugs; 2020 Mar; 34(3):299-310. PubMed ID: 31994024
[TBL] [Abstract][Full Text] [Related]
12. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
13. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
[TBL] [Abstract][Full Text] [Related]
14. Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.
Vasiliu O
Front Pharmacol; 2022; 13():884155. PubMed ID: 35847011
[TBL] [Abstract][Full Text] [Related]
15. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
16. Investigational drugs for treating major depressive disorder.
Dhir A
Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
[TBL] [Abstract][Full Text] [Related]
17. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravenous ketamine and intranasal esketamine with dose escalation for Major depression: A systematic review and meta-analysis.
Seshadri A; Prokop LJ; Singh B
J Affect Disord; 2024 Jul; 356():379-384. PubMed ID: 38537759
[TBL] [Abstract][Full Text] [Related]
19. New medications for treatment-resistant depression: a brief review of recent developments.
Thase ME
CNS Spectr; 2017 Dec; 22(S1):39-48. PubMed ID: 29350129
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
[No Abstract] [Full Text] [Related]
[Next] [New Search]